A study to determine the reliability of a top mount actuation indicator when used with levalbuterol tartrate [levosalbutamol] HFA [hydrofluoroalkane] MDI [metered-dose inhaler] in adult and pediatric subjects with asthma or chronic obstructive pulmonary disease
Latest Information Update: 11 Aug 2023
Price :
$35 *
At a glance
- Drugs Levosalbutamol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Sponsors Sumitomo Pharma America
- 22 Jan 2008 New trial record.